Charles Schwab Investment Management Inc Taysha Gene Therapies, Inc. Transaction History

Charles Schwab Investment Management Inc

$601 Billion
Q3 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,846,510 shares of TSHA stock, worth $7.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,846,510

Previous 491,709 275.53%

Holding current value

$7.77 Million

Previous $1.14 Million 412.42%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$2.34 - $3.29 $3.17 Million - $4.46 Million	1,354,801 Added 275.53%	1,846,510 $5.82 Million
Q2 2025 Aug 12, 2025	SELL	$1.13 - $2.9 $62,623 - $160,715	-55,419 Reduced 10.13%	491,709 $1.14 Million
Q1 2025 Sep 15, 2025	BUY	$1.39 - $2.05 $77,032 - $113,608	55,419 Added 11.27%	547,128 $760,000
Q1 2025 May 09, 2025	BUY	$1.39 - $2.05 $101,290 - $149,385	72,871 Added 15.37%	547,128 $760,000
Q4 2024 Feb 06, 2025	BUY	$1.27 - $3.24 $14,465 - $36,903	11,390 Added 2.46%	474,257 $820,000

Q3 2024 Nov 12, 2024	BUY	$2.01 - $2.46 $66,577 - $81,482	33,123 Added 7.71%	462,867 $930,000
Q2 2024 Aug 12, 2024	BUY	$2.04 - $4.17 $771,695 - $1.58 Million	378,282 Added 735.07%	429,744 $962,000
Q1 2024 May 08, 2024	BUY	$1.43 - $3.25 $50,510 - $114,796	35,322 Added 218.85%	51,462 $147,000
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $131,244 - $368,380	-74,571 Reduced 82.21%	16,140 $32,000
Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $184,345 - $505,272	-74,634 Reduced 45.14%	90,711 $338,000
Q1 2022 May 13, 2022	BUY	$5.22 - $11.86 $14,537 - $33,030	2,785 Added 1.71%	165,345 $1.08 Million
Q4 2021 Feb 11, 2022	BUY	$11.43 - $19.2 $47,468 - $79,737	4,153 Added 2.62%	162,560 $1.89 Million
Q3 2021 Nov 16, 2021	BUY	$15.82 - $21.57 $1.13 Million - $1.54 Million	71,377 Added 82.01%	158,407 $2.95 Million
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $555,301 - $759,401	28,787 Added 49.43%	87,030 $1.85 Million
Q1 2021 May 17, 2021	BUY	$20.3 - $31.75 $122,023 - $190,849	6,011 Added 11.51%	58,243 $1.18 Million
Q4 2020 Feb 16, 2021	BUY	$19.14 - $28.13 $999,720 - $1.47 Million	52,232 New	52,232 $1.39 Million

Others Institutions Holding TSHA

# of Institutions

161

Shares Held

247M

Call Options Held

463K

Put Options Held

246K

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $204M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Taysha Gene Therapies, Inc. Transaction History